Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

This study has been withdrawn prior to enrollment.
(Sponsor has decided to not proceed with this study.)
Information provided by:
Abbott Identifier:
First received: May 22, 2009
Last updated: February 25, 2010
Last verified: February 2010

This is a Phase 2b, open-label, multicenter, global study assessing the safety and efficacy of ABT-263 in subjects with B-cell CLL who have failed at least one prior fludarabine-containing regimen.

Condition Intervention Phase
B-cell Chronic Lymphocytic Leukemia
Drug: ABT-263
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2b Monotherapy Study of ABT-263 in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Resource links provided by NLM:

Further study details as provided by Abbott:

Primary Outcome Measures:
  • Assess the safety of ABT-263 by evaluating study drug exposure, adverse events, serious adverse events, all deaths, as well as changes in laboratory determinations and vital sign parameters. [ Time Frame: monthly (at a minimum) ] [ Designated as safety issue: Yes ]
  • Assess the objective response rate (partial response [PR] and confirmed complete response [CR]) of B-cell CLL subjects treated with ABT-263. [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess the effects of ABT-263 on duration of overall response, PFS and overall survival in subjects with B-cell CLL. [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]
  • Assess the effects of ABT-263 on time to response, 12-month survival rate, time to disease progression (TTP), and disease control rate in subjects with B-cell CLL . [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]
  • Investigate the effects of ABT-263 on quality of life (FACT-Leu and EQ-5D), ECOG performance status, and biomarkers in subject with B-cell CLL. [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: March 2010
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: ABT-263

Continuous dosing until disease progression using one of the following formulations:

25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed

Other Name: ABT-263


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • >= 18 yrs of age, have B-cell CLL, failed at least 1 prior fludarabine-containing regimen.
  • Refractory to 1 fludarabine-containing regimen is defined as failure to achieve at least PR to the last fludarabine-containing regimen received, or disease progression while receiving the last fludarabine-containing regimen, or disease progression in responders (i.e., achieved a PR or CR) within 6 mos of the last cycle of the last fludarabine-containing regimen received (e.g., fludarabine monotherapy, FR, or FC) or in responders (i.e., achieved a PR or CR ) within 24 mos of the last cycle of FCR.
  • Intolerant to fludarabine is defined as discontinuation of therapy within 2 cycles due to side effects/toxicity from the last fludarabine-containing regimen.
  • ECOG score of <=1.
  • Adequate coagulation, renal, & hepatic function at Screening as follows:

    • Serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 50 mL/min;
    • AST & ALT <= 3.0 x ULN;
    • Bilirubin <= 1.5 x ULN.
  • Gilbert's Syndrome may have a Bilirubin > 1.5 x ULN; aPTT, PT, not to exceed 1.2 x ULN.
  • Adequate bone marrow (BM) independent of any growth factor support (with the exception of subjects with BM heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve adequate BM) at Screening as follows:

    • ANC >= 1000/µL;
    • Platelets >= 75,000/mm3 (entry platelet count must be independent of transfusion within 14 days of Screening);
    • Hemoglobin >= 9.0 g/dL.
  • History of autologous BM transplant must be > 6 mos post transplant (prior to the 1st dose of study drug) & have adequate BM independent of any growth factor support (with the exception of subjects with BM that is heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve adequate BM) at Screening as follows:

    • ANC >= 1500/µL;
    • Platelets >= 125,000/mm3;
    • Hemoglobin >= 10.0 g/dL.
  • Female subjects must be surgically sterile, postmenopausal (at least 1 year), or have negative results on a pregnancy test.
  • All female subjects not surgically sterile or postmenopausal (at least 1 year) & non-vasectomized male subjects must practice birth control.

Exclusion Criteria:

  • History/clinically suspicious for cancer-related CNS disease.
  • Undergone allogeneic stem cell transplant.
  • Undergone autologous stem cell transplant w/i 6 mos prior to 1st dose.
  • History/predisposing condition of bleeding or currently exhibits signs of bleeding.
  • Recent history of non-chemotherapy induced thrombocytopenic associated bleeding w/i 6 mos prior to 1st dose.
  • Active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
  • Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions w/i 1 yr prior to 1st dose.
  • Currently receiving/requires anticoagulation therapy or any drugs or herbal supplements that affect platelet function, with the exception of low-dose anticoagulation medications used to maintain the patency of a central IV catheter.
  • Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease.
  • Positive for HIV, Hepatitis B, or Hepatitis C.
  • Previous or current malignancies w/i the last 3 yrs:

    • except adequately treated in situ carcinoma of the cervix uteri;
    • basal or squamous cell carcinoma;
    • in situ carcinoma of the bladder;
    • or previous malignancy confined and surgically resected with curative intent.
  • Has Prolymphocytic leukemia or Richter's transformation to an aggressive B-cell malignancy.
  • Exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to uncontrolled systemic infection or diagnosis of fever and neutropenia w/i 1 week prior to study drug.
  • Prior exposure to ABT-263.
  • Received antibody therapy w/i 30 days prior to 1st dose.
  • Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, or any investigational therapy w/i 14 days prior to the 1st dose, or has not recovered to <Gr2 clinically significant AE(s) /toxicity(s) of the previous therapy.
  • Received steroid therapy for anti-neoplastic intent, w/i 7 days prior to the 1st dose with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids.
  • Received aspirin w/i 7 days prior to the 1st dose.
  • Consumed grapefruit or grapefruit products w/i 3 days prior to 1st dose.
  • Females pregnant or breast-feeding.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Sari Enschede, MD, Abbott Laboratories Identifier: NCT00918450     History of Changes
Other Study ID Numbers: M10-738
Study First Received: May 22, 2009
Last Updated: February 25, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Neoplasms by Histologic Type
Leukemia, B-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on April 17, 2014